Information on IGHV molecular genetic test
This molecular genetic test is designed to detect mutational status of the immunoglobulin heavy-chain variable (IGHV) region gene in clonal B-cell populations1
- A common definition for unmutated IGHV is a result <2% (≥98% homology) distinct from the most closely matched VH germ line, but individual labs may vary slightly1,2
- Mutated IGHV is independently associated with a relatively favorable prognosis1
- In contrast, patients with unmutated IGHV have poorer clinical prognoses with faster disease progression and shorter overall survival compared to mutated IGHV1,3
Sample form for ordering molecular genetics tests
This is one example of how an order form might look; forms and terminology (eg, IgVH vs IGHV) may differ from lab to lab.
IGHV molecular mutation testing is available as part of a comprehensive CLL panel at these laboratories:
IGHV molecular mutation testing is available as a stand-alone test at these laboratories:
CLL=chronic lymphocytic leukemia, IGHV=immunoglobulin heavy-chain variable region gene.
Review helpful resources for you, your patients, and your practice.
References: 1. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760. 2. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-1854 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma V.4.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed April 15, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Share this page